Skip to content Skip to sidebar Skip to footer

Anne Li                                                                                                May 13th, 2017

 

The first study used genomic profiling to identify targeted therapies that resulted in benefits for patients with pancreatic cancer, including one whose tumor contained a mutation in the anaplastic lymphoma kinase (ALK) gene. In the second study, researchers used existing drugs already treating other types of ALK-mutated cancers to improve outcomes in pancreatic cancer patients with the same genetic alterations.
 
See original article at: https://www.sciencedaily.com/releases/2017/05/170509161127.htm

Leave a comment